Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, February 7, 2013

Chelation: No Benefit in Ischemic Stroke

This is one of those alternative treatments. Why would clearing out arteries have any benefit if the forces of the neuronal cascade of death are allowed to continue?
http://www.medpagetoday.com/Cardiology/Strokes/37247
A chelating agent targeting zinc that showed promise in early studies failed to improve outcomes in patients with acute ischemic stroke, a prematurely-terminated randomized trial showed.
At 90 days after the stroke, the distribution of modified Rankin scores was similar in the patients who received the agent -- DP-b99 -- and those who received placebo (P=0.21), according to Kennedy Lees, MD, of the University of Glasgow in Scotland, and colleagues.
Rates of mortality and adverse events did not differ between the two groups, the researchers reported online in Stroke: Journal of the American Heart Association. The findings also were presented at the International Stroke Conference in Honolulu.

More:
Posted by at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)